title: [Focal therapy for prostate cancer in Germany - 2014 status].
abstract: BACKGROUND
  In localized low-risk prostate cancer (PCa), there is a therapeutic dilemma between possible overtreatment by one of the standard therapies and potentially insufficient cancer control by active surveillance (AS). Focal therapy (FT) provides an alternative therapeutic option as it aims to preserve the organ and to eliminate the cancer focus at the same time.
  
  
  METHODS
  In this article the current state of FT for localized low-risk prostate carcinoma in Germany is described. In addition, criteria that should be used to select patients for FT are proposed.
  
  
  RESULTS
  Currently, the effectiveness of FT is under evaluation by two multicenter, prospective studies in Germany: TOOKAD and HEMI. However, localized low-risk prostate carcinoma remains a diagnostic challenge: Multiparametric MRI as well as histopathological second opinion are considered mandatory in addition to transrectal biospy.
  
  
  CONCLUSIONS
  The oncological outcome of both the TOOKAD and HEMI study will be crucial for any form of FT for prostate carcinoma in Germany in the future. However, there is a remarkably high acceptance of FT among patients.
authors.affiliation: Urologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, Klinikum Großhadern, Marchioninistraße 15, 81377, München, Deutschland, alexander.roosen@med.uni-muenchen.de.
authors.forename: A
authors.initials: A
authors.lastname: Roosen
authors.forename: R
authors.initials: R
authors.lastname: Ganzer
authors.forename: B
authors.initials: B
authors.lastname: Hadaschik
authors.forename: J
authors.initials: J
authors.lastname: Köllermann
authors.forename: A
authors.initials: A
authors.lastname: Blana
authors.forename: T
authors.initials: T
authors.lastname: Henkel
authors.forename: A-B
authors.initials: AB
authors.lastname: Liehr
authors.forename: D
authors.initials: D
authors.lastname: Baumunk
authors.forename: S
authors.initials: S
authors.lastname: Machtens
authors.forename: G
authors.initials: G
authors.lastname: Salomon
authors.forename: L
authors.initials: L
authors.lastname: Sentker
authors.forename: U
authors.initials: U
authors.lastname: Witsch
authors.forename: K U
authors.initials: KU
authors.lastname: Köhrmann
authors.forename: M
authors.initials: M
authors.lastname: Schostak
mesh_terms: D019317:Evidence-Based Medicine; D005858:Germany; D006801:Humans; D008297:Male; D019060:Minimally Invasive Surgical Procedures / Q000379:methods*; D059351:Organ Sparing Treatments / Q000379:methods*; D011379:Prognosis; D011468:Prostatectomy / Q000379:methods*; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D020266:Radiotherapy, Conformal / Q000379:methods*; D018570:Risk Assessment / Q000379:methods; D016896:Treatment Outcome; D057832:Watchful Waiting / Q000379:methods